Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAsset Writedowns and ImpairmentBeginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aytu Biopharma (AYTU) Gains from Sales and Divestitures: 2018-2025

Historic Gains from Sales and Divestitures for Aytu Biopharma (AYTU) over the last 5 years, with Sep 2025 value amounting to $1,618.

  • Aytu Biopharma's Gains from Sales and Divestitures fell 72.69% to $1,618 in Q3 2025 from the same period last year, while for Sep 2025 it was $1,618, marking a year-over-year decrease of 72.69%. This contributed to the annual value of $11,193 for FY2025, which is 56.90% down from last year.
  • According to the latest figures from Q3 2025, Aytu Biopharma's Gains from Sales and Divestitures is $1,618, which was down 85.54% from $11,193 recorded in Q2 2025.
  • Aytu Biopharma's 5-year Gains from Sales and Divestitures high stood at $642,696 for Q2 2022, and its period low was $1,618 during Q3 2025.
  • Its 3-year average for Gains from Sales and Divestitures is $16,343, with a median of $11,193 in 2025.
  • In the last 5 years, Aytu Biopharma's Gains from Sales and Divestitures spiked by 300.18% in 2022 and then crashed by 93.40% in 2023.
  • Over the past 5 years, Aytu Biopharma's Gains from Sales and Divestitures (Quarterly) stood at $90,836 in 2021, then plummeted by 66.17% to $30,733 in 2022, then slumped by 60.34% to $12,189 in 2023, then tumbled by 35.57% to $7,853 in 2024, then plummeted by 72.69% to $1,618 in 2025.
  • Its Gains from Sales and Divestitures stands at $1,618 for Q3 2025, versus $11,193 for Q2 2025 and $9,577 for Q1 2025.